For research use only
| Cat No. | ABC-TC3885 |
| Product Type | Bone Marrow Mononuclear Cells |
| Cell Type | Mononuclear Cell |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Bone Marrow |
| Disease | Mantle Cell Lymphoma |
| Storage | Liquid Nitrogen |
Human Mantle Cell Lymphoma Bone Marrow Mononuclear Cells (Newly Diagnosed/Untreated) provide a critical resource for hematology and oncology.
Human Mantle Cell Lymphoma Bone Marrow Mononuclear Cells (Newly Diagnosed/Untreated), derived from newly diagnosed and untreated patients, are malignant lymphoid cells associated with mantle cell lymphoma. These cells typically exhibit a relatively uniform population of small-to-medium-sized lymphoid cells. These malignant B cells evade normal cell cycle regulation, leading to uncontrolled proliferation and resistance to apoptosis. They infiltrate the bone marrow, lymph nodes, and frequently the gastrointestinal tract, causing systemic disease. Mantle cell lymphoma cells often harbor mutations in ATM, TP53, and NOTCH1, contributing to their aggressive clinical behavior. The cells are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, syphilis, mycoplasma, fungi, yeast, and bacteria.
| Product Code | Human Mantle Cell Lymphoma Bone Marrow Mononuclear Cells (Newly Diagnosed/Untreated), MCL BM-MNCs (ND), Mantle Cell Lymphoma Bone Marrow MNCs Untreated, Newly Diagnosed MCL BM Mononuclear Cells |
| Species | Human |
| Cat.No | ABC-TC3885 |
| Product Category | Primary Cells |
| Size/Quantity | 1 vial |
| Cell Type | Mononuclear Cell |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Bone Marrow |
| Disease | Mantle Cell Lymphoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Bone Marrow Mononuclear Cells |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
Human Mantle Cell Lymphoma Bone Marrow Mononuclear Cells (Newly Diagnosed/Untreated) serve as a valuable model for understanding mantle cell lymphoma pathogenesis, particularly the dysregulation of cell cycle control and the role of key mutations in disease progression. They are essential for preclinical drug testing, including evaluating novel targeted therapies such as BTK inhibitors, BCL-2 antagonists, and CD19-directed CAR-T cell immunotherapies.
When you publish your research, please cite our product as "AcceGen Biotech Cat.# XXX-0000". In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).